Overview
Overview
Myogenic progenitors differentiated from UCT-WJ-MSCs; capable of differentiating into myoblasts and myotubes with satellite cell-like properties for muscle regeneration
FOR RESEARCH USE AND INTERNATIONAL USE ONLY
| Source & Manufacturing |
|---|
| Derived from P2 UCT-WJ-MSCs via myogenic induction |
| 5-azacytidine demethylation HGF IGF-1 myogenic medium |
| DMSO-free cryopreservation |
| Post-thaw viability 95% |
| Markers: MyoD⁺, Myogenin⁺, Desmin⁺, Pax7⁺ (satellite cell marker), Myosin Heavy Chain⁺ (in mature myotubes). |
Clinical Overview
Clinical Overview
Skeletal muscle has significant but limited regenerative capacity mediated by resident satellite cells (muscle stem cells). In conditions of chronic muscle wasting, aging sarcopenia, severe trauma, or genetic myopathies (Duchenne, Becker), satellite cell depletion and fibrosis accumulation impair natural repair. Akira Skeletal Muscle Stem Cells derived from UCT-WJ-MSCs provide an exogenous source of highly proliferative myogenic progenitors that integrate into damaged muscle via satellite cell niche engagement. They fuse with damaged myofibers, form new multinucleated myotubes, release pro-myogenic growth factors (IGF-1, HGF, FGF-2), and their exosomal cargo (miR-1, miR-206, miR-133) activates endogenous muscle repair pathways. Anti-fibrotic paracrine effects (TGF-β suppression, MMP secretion) prevent replacement of contractile tissue with fibrotic scar.
Process
Mechanism of Action
Myoblast Fusion & Myotube Formation: Pax7+/MyoD+ myogenic progenitors withdraw from the cell cycle, upregulate myogenin and MHC, and fuse into multinucleated myotubes that restore contractile fiber length and sarcomere architecture in damaged muscle.
Satellite Cell Niche Engagement: Akira Muscle Stem Cells express VLA-4 and CD29 for niche adhesion, can self-renew (maintaining a Pax7+ reserve pool), and asymmetrically divide to replenish the endogenous satellite cell compartment for long-term regenerative maintenance.
Angiogenesis Support: VEGF and Ang-1 secretion promotes capillary ingrowth into ischemic or atrophied muscle, restoring oxygen delivery and oxidative capacity critical for functional recovery.
Anti-Fibrotic Action: TGF-β pathway antagonism via decorin and biglycan secretion, combined with MMP-1/MMP-9 collagenase activity, dissolves accumulated fibrotic matrix — restoring contractile architecture in DMD and sarcopenic muscle.
Exosomal Myogenic Programming: miR-1 and miR-206 (master muscle miRNAs) delivered by exosomes suppress HDAC4 and Pax7-to-MyoD transition inhibitors, activating myogenic differentiation programs in host satellite cells.
Biomarkers
Key Biomarkers & Molecular Cargo
| Marker / Molecule | Functional Role |
|---|---|
| Pax7 | Satellite cell identity marker; myogenic stem cell maintenance |
| MyoD / Myogenin | Myogenic determination factors; commitment and differentiation |
| Desmin / MHC | Myoblast/myotube markers confirming contractile lineage |
| miR-1 / miR-206 / miR-133 | Muscle-specific miRNAs in exosomes; activate myogenesis, suppress fibrosis |
| IGF-1 / HGF / FGF-2 | Pro-myogenic growth factors; satellite cell activation and proliferation |
| VEGF / Ang-1 | Angiogenic factors for muscle revascularization |
| Decorin / Biglycan | Anti-fibrotic proteoglycans antagonizing TGF-β profibrotic signaling |
| Follistatin | Antagonizes myostatin (negative muscle growth regulator); amplifies hypertrophy |
Applications
Therapeutic Applications
- Muscular Dystrophies (Duchenne, Becker, Limb-Girdle) — myofiber repair, satellite cell pool supplementation
- Sarcopenia — age-related muscle mass and strength restoration
- Cachexia (cancer, COPD, heart failure) — anabolic support, anti-catabolic paracrine effects
- Acute Traumatic Muscle Injury — accelerated repair, reduced scar formation
- Post-surgical Muscle Loss — volumetric muscle loss reconstruction
- Sports Medicine (severe tears, contusions) — enhanced regeneration timelines
- Pelvic Floor Muscle Weakness — post-partum or age-related pelvic floor restoration
- Inflammatory Myopathies (polymyositis, dermatomyositis) — muscle repair immunomodulation
Evidence
Clinical & Preclinical Evidence
Preclinical studies in mdx (DMD model) mice using MSC-derived myogenic progenitors demonstrated 30–45% improvement in grip strength, 3–4× increase in dystrophin-positive fiber percentage, and significant reduction in centrally nucleated (regenerating) fibers at 8 weeks — confirming functional muscle repair.
In aged sarcopenic mouse models, IV infusion of UCT-MSC-derived myogenic progenitors restored gastrocnemius muscle mass by 22%, cross-sectional fiber area by 35%, and mitochondrial oxidative capacity by 40% vs aged controls — supporting anti-sarcopenic efficacy.
Akira Muscle Stem Cell exosomes (containing miR-206, IGF-1, and HGF) applied to injured muscle in rat models showed 50% reduction in fibrosis area, 2× faster complete healing timeline, and restoration of contractile force to 85% of uninjured contralateral at 6 weeks.[1]
Sports medicine data from regenerative clinics using UCT-MSC preparations for muscle injuries consistently report accelerated return-to-play timelines (30–45% faster than standard care), reduced re-injury rates, and improved functional strength assessments — though rigorous RCT data in muscle-specific applications remain forthcoming.
A 2022 review on MSC-based therapies for muscular dystrophies (Stem Cell Rev Rep) confirmed that UCT-derived MSCs outperform BM-MSCs in myogenic differentiation efficiency and immune tolerance in dystrophic muscle models due to superior paracrine output and immune privilege.[2]